Drugs / PE0105
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05801237 | Sep 2023 → Sep 2026 overdue | — | Shanghai HyaMab Biotech Co.,Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06026501 | Aug 2023 → Aug 2027 expected | neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PE0105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05801237 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-PD1 Human Monoclonal Antibody Injection” NCT05801237 ↗ |
| Route | Intravenous | “PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w）” NCT06026501 ↗ |